Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 314
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | ||
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | ||
| NCT05886244 | Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | ||
| NCT03075904 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT01770951 | A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | ||
| NCT05683678 | US Selumetinib Registry | ||
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria | ||
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | ||
| NCT01303952 | Therapy of Chronic Cold Agglutinin Disease With Eculizumab | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ||
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease | ||
| NCT06079359 | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | ||
| NCT01700179 | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants | ||
| NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy | ||
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | ||
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | ||
| NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | ||
| NCT00312039 | Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation | ||
| NCT06398158 | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT07157787 | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | ||
| NCT01454986 | Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects | ||
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | ||
| NCT04233073 | Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery | ||
| NCT06183931 | Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | ||
| NCT00739505 | Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP) | ||
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | ||
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT05981092 | A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) | ||
| NCT07337395 | Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab | ||
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | ||
| NCT02796885 | Characterisation of Adult-Onset Hypophosphatasia | ||
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | ||
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT04526210 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | ||
| NCT01528917 | An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype | ||
| NCT01335165 | Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | ||
| NCT01755429 | To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients | ||
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | ||
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | ||
| NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | ||
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) |
